New hope for seniors with aggressive lymphoma: gentler chemo plus targeted drug shows promise
NCT ID NCT04594798
First seen Jan 04, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This study tests a new combination of drugs for people aged 75 and older with a type of blood cancer called DLBCL. The treatment pairs a targeted therapy (polatuzumab vedotin) with a lower-dose chemotherapy regimen (R-miniCHP) to see if it can keep the cancer from growing longer while being safer for older patients. About 39 participants will be followed to measure how long they live without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.